BrainStorm has attempted to gain market approval for NurOwn without success but remains committed to developing the cell therapy.

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

NEW YORK – Singapore's Experimental Drug Development Center (EDCC) will use Engine Biosciences' machine learning platform to advance precision cancer therapies, according to a partnership announced ...

In a mouse model, a single dose of ATL-201 durably suppressed seizures and improved behavior through six months, according to the firm.

The approval was based on results from a Phase III trial showing that Opdivo-Yervoy improved outcomes against Opdivo alone and chemo alone.

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

NEW YORK – Adaptin Bio on Monday said it has completed a reverse merger with a subsidiary of Unite Acquisition 1 Corp to bring the company public and closed a private placement worth up to $7.7 ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.